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Abstract
Background: Apoptotic cell-based therapies have been proposed to treat chronic inflammatory diseases. The aim
of this study was to investigate the effect of intravenous (i.v.) apoptotic cell infusion in ongoing collagen-induced
arthritis (CIA) and the interaction of this therapy with other treatments used in rheumatoid arthritis (RA), including
methotrexate (MTX) or anti-TNF therapy.
Methods: The effects of i.v. apoptotic cell infusion were evaluated in a CIA mouse model in DBA/1 mice
immunized with bovine type II collagen. The number and functions of antigen-presenting cells (APC), regulatory
CD4+ T cells (Treg), and circulating anti-collagen auto-antibodies were analyzed in CIA mice.
Results: Treatment of arthritic mice with i.v. apoptotic cell infusion significantly reduced the arthritis clinical score.
This therapeutic approach modified T cell responses against the collagen auto-antigen with selective induction of
collagen-specific Treg. In addition, we observed that APC from apoptotic-cell-treated animals were resistant to
toll-like receptor ligand activation and favored ex vivo Treg induction, indicating APC reprogramming. Apoptotic
cell injection-induced arthritis modulation was dependent on transforming growth factor (TGF)-β, as neutralizing
anti-TGF-β antibody prevented the effects of apoptotic cells. Methotrexate did not interfere, while anti-TNF therapy
was synergic with apoptotic-cell-based therapy.
Conclusion: Overall, our data demonstrate that apoptotic-cell-based therapy is efficient in treating ongoing CIA,
compatible with current RA treatments, and needs to be evaluated in humans in the treatment of RA.
Background
Rheumatoid arthritis (RA) is an autoimmune disorder
characterized by chronic inflammation of the synovial
joints leading to the destruction of cartilage, bone, and
ligaments [1]. Conventional treatment of RA with
disease-modifying anti-rheumatic drugs (DMARD) aims
to limit disease symptoms, delay or prevent future joint
destruction, and target low disease activity or remission.
Low-dose methotrexate (MTX) is the traditional DMARD
administered weekly either alone or in combination
therapy. MTX has been proven safe and efficient [2].
However, nearly a quarter of patients treated with MTX
have to discontinue treatment because of poor re-
sponses, adverse effects (e.g., hepatic, gastrointestinal,
hematological, renal, or pulmonary toxicity), or both [3,
4]. Biological agents, such as anti-TNF therapy, com-
bined with MTX have significantly improved the treat-
ment of RA. However, again, some RA patients are
refractory or contraindicated to these agents [4, 5], and
thus, new therapeutic strategies are needed.
Apoptotic cell administration has been shown to con-
trol chronic inflammatory disorders by diminishing the
pro-inflammatory state and to induce or restore toler-
ance to auto-antigens by inhibiting pathogenic T or B
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cell responses and by inducing pro-tolerogenic/regulatory
cells [6–8]. Prevention of arthritis by apoptotic cell injec-
tion has been reported in mouse and rat models [9–12].
Prevention means that apoptotic cells are infused at the
time of arthritic disease induction (i.e., at time of
immunization with auto-antigens), which does not mimic
the clinical situation. However, intravenous (i.v.) apoptotic
cell infusion can be used for experimental treatment of
disease, such as in sepsis [13, 14]. These data are interest-
ing, because apoptotic cell administration during the dis-
ease (i.e., as treatment) protects mice from sepsis-induced
death [13, 14], while infusion 5 days before sepsis (as pre-
vention) worsens mice survival, possibly by decreasing the
capacity to secrete interferon (IFN)-γ [15]. As in arthritis
models [9–12], sepsis is controlled independently of the
apoptotic cell origin [13, 14]. Recently, a phase 1/2a clin-
ical study was conducted in 13 patients who received i.v.
donor apoptotic cell infusion the day before allogeneic
hematopoietic cell transplantation in order to alleviate the
occurrence of acute graft-versus-host disease (GvHD)
[16]. The apoptotic cell number infused in patients was
transposed from animal models [17]. There was no spe-
cific toxicity associated with i.v. apoptotic cell infusion.
Historical data on acute GvHD and the available literature
suggest promising potential for GvHD prophylaxis [16].
This clinical study opens the way to apoptotic cell-based
therapy in other clinical settings already assessed in ex-
perimental models, such as RA. Here, we propose to as-
sess whether i.v. apoptotic cell infusion may control
ongoing collagen-induced arthritis (CIA) and determine
the mechanisms involved by focusing on antigen present-
ing cells (APC) and regulatory CD4+ T cells (Treg).
A major concern with novel therapeutic approaches,
such as apoptotic-cell-based therapy, is the interaction
with other treatments received simultaneously by the pa-
tients. For instance, MTX, the gold standard treatment
for RA, may be given alongside biologic agents, including
anti-TNF therapy. We have already studied the interac-
tions of i.v. apoptotic cell infusion with immunosuppres-
sive drugs routinely used in the context of allogeneic
hematopoietic cell transplantation. Rapamycin (sirolimus)
has been shown to exert a synergic effect, while cyclo-
sporine A neutralizes apoptotic-cell-induced allogeneic
hematopoietic cell engraftment [18]. This kind of study
has to be extended to other conventional drugs in the
treatment of RA, such as MTX and anti-TNF agents. We
also addressed interactions between i.v. apoptotic cell in-
fusion and MTX or anti-TNF therapy in the CIA model.
Methods
Mice
Female DBA/1, (Janvier, Le Genest-Saint-Isle, France)
and C57Bl/6 (Charles River Laboratories, L’Arbresle,
France) mice, 8–10 week old, were housed in filter-top
cages and fed a standard diet with freely available food
and sterile water (Plexx, Elst, Netherlands), at the
UMR1098 animal facility (agreement number D25-056-
7). All experimental studies were approved (number
02831) by the local ethics committee (Comité d’éthique
Bisontin en Expérimentation animale, number 58) and
the French Ministry of Higher Education and Research
(Ministère de l’Enseignement Supérieur et de la
Recherche), and was conducted in accordance with the
European Union Directive 2010/63.
Induction of collagen-induced arthritis
The induction of arthritis has been described previously
in detail [19]. Briefly, DBA/1 susceptible mice were im-
munized by subcutaneous injection at the tail base with
100 μL of bovine type II collagen (hereafter called colla-
gen) dissolved in 0.05 M acetic acid (4 mg/mL; MD Bio-
products, Zurich, Switzerland) emulsified in an equal
volume of complete Freund’s adjuvant (CFA, 10 mg of
Mycobacterium tuberculosis (MBT) strain H37Ra (Difco,
Detroit, USA) per milliliter of incomplete Freund adju-
vant (Sigma Aldrich, St Louis, MO, USA)).
Arthritis developed in all mice 20 to 25 days after colla-
gen immunization. Arthritis severity was determined by
daily blinded visual examination of the paws as follows: 0 =
no change; 1 = redness or swelling of one toe; 2 = redness
or swelling of two toes; 3 = redness or severe swelling of
two toes or more digits, erythema, or swelling involving the
entire paw; and 4 = redness or swelling of the entire paw,
spreading to the ankle. The clinical score for each mouse
was the result of the sum of scores for the four limbs (max-
imum score = 16). When arthritis reached a clinical score
of 7–8, mice received apoptotic cells i.v. (5.10e6 cells/
300 μL/mouse, or as indicated), or vehicle (300 μL of PBS).
MTX (provided by the University Hospital, Besançon,
France), was given intraperitoneally (i.p.) once a week
(15 mg/kg), starting on the day of apoptotic cell injection.
Anti-TGF-β antibody (clone 1D11 (R&D Systems, Lille,
France) or 2G7 clone provided by Prof. L. Chatenoud
(Necker Hospital, Paris, France)) was given i.p. on the day
of apoptotic cell injection (150 μg/mouse) and 48 h later
(100 μg/mouse). Anti-TNF antibody (clone TN3-19.12 (BD
Biosciences; Le Pont de Claix, France)) was given i.p. on
the day of apoptotic cell injection (300 μg/mouse) and at
72 h, 6 days, and 9 days later (300 μg/mouse/injection).
CIA mice that did or did not receive apoptotic cells
were killed on days 10 to 12 post treatment and were
harvested for blood, lymphoid organs, and ankles for
further analysis.
Induction of apoptotic cells
Cells were issued from the thymus of naïve DBA/1 mice
and submitted to a 35-Gy dose of x-ray irradiation (Raycell
blood irradiator; Best Theratronic, Ottawa, ON, Canada)
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followed by 6-h culture in complete DMEM Glutamax-I
(Life Technologies, Gaithersburg, MD, USA) supple-
mented with 10 % heat-inactivated FCS (Life Tech-
nologies), 1 % penicillin/streptomycin, 10 mM HEPES
buffer (Sigma Aldrich), 10 mM nonessential amino
acids (Invitrogen, Cergy Pontoise, France), and 0.05 mM
2-mercaptoethanol (Sigma Aldrich), to allow apoptotic
changes to occur before injection [20]. Apoptotic cells
were then washed twice in PBS before injection into the
tail vein in 300 μL of PBS. Non-treated arthritic mice re-
ceived PBS as control. Apoptosis was confirmed using
fluorescein isothiocyanate (FITC) or phycoerythrin (PE)-
conjugated annexin V staining and 7-aminoactinomycin
D2 (7-AAD) exclusion (BD Biosciences) and flow cytome-
try analysis. At the time of injection, apoptotic cells were
mainly early-stage apoptotic cells (70–85 % of cells were
annexin V+ and 7-AAD–; less than 10 % of cells were
7-AAD+) [20].
Ex vivo analysis of T cells and antigen presenting cells
Lymphoid organs, spleen, and inguinal and axillary
lymph nodes were harvested and dissociated, and eryth-
rocytes were removed by osmotic shock. After washing
with PBS, lymphoid cells were directly stained for CD4
(clone RM4-5, BD Biosciences), CD25 (clone PC-61, BD
Biosciences) and Foxp3 (clone FJK-16 s, eBioscience) ex-
pression following manufacturer’s instructions. Stained
cells were analyzed using a FACS Canto II cytometer
with Diva software (BD Biosciences).
Cells issued from lymph nodes were also plated and
activated using CD3-specific antibodies (Ab) (0.5 μg/mL;
clone 145-2C11; Biolegend) or collagen protein as indi-
cated and cultured for 5 days in complete medium. T
cell proliferation was then evaluated using 5-Bromo-2’-
deoxyuridine (BrdU) incorporation and counting (Perkin
Elmer, Waltham, MA, USA). Spleen CD4+CD25+ T
cells were enriched using immuno-magnetic cell sorting
(MACS; CD4+CD25+ Regulatory T Cell Isolation Kit;
Miltenyi Biotec, Paris, France) according to manufac-
turer’s instructions and used in collagen-specific or
MBT-specific proliferation assays or in CD3/CD28-stim-
ulated T cell cultures at different concentrations. For
collagen-specific or MBT-specific co-cultures, naïve CD4
+CD25– T cells were isolated from CIA mice by MACS
(Miltenyi Biotec) and cultured (100.10e3 cells) with
CD11c+ dendritic cells (DC) (50.10e3 cells) also isolated
from CIA mice by MACS (CD11c MicroBeads (Miltenyi
Biotec)), in the presence of 50 μg/mL of collagen (MD
Bioproducts, Zürich, Switzerland) or MBT (Difco) pro-
tein. For CD3/CD28-stimulated T cell cultures, CD4
+CD25– naïve T cells were isolated from naïve DBA1
mice and cultured in the presence of coated anti-CD3
(clone 145-2C11) and soluble anti-CD28 (clone 37.51)
antibodies (2.0 and 0.5 μg/mL, respectively). After
adding sorted Treg and after 4 days of culture, T cell
proliferation was assessed by BrdU incorporation and
counting.
Conventional DC (cDC (CD11c+)), plasmacytoid DC
(mPDCA+B220+) and macrophages (CD11b+) were ana-
lyzed in the spleen for ex vivo expression of costimula-
tory molecules CD40 (clone 3/23, Biolegend) and major
histocompatibility class (MHC) II IA/IE (clone M5/
114.15.2, Biolegend) molecules by FACS (with the corre-
sponding labeled antibodies). In addition, cDC, pDC and
macrophages were isolated by MACS and cultured in
the presence of CpG-ODN2216 (for pDC, 12 μg/mL
(Invivogen, Toulouse, France)) or lipopolysaccharide
(LPS) (for cDC and macrophages, 1 μg/mL (Sigma Al-
drich, St Louis, MO, USA)) for 24 h in complete
medium and the same marker expression was assessed
by FACS. Isolated APC were also cultured with allogen-
eic naïve CD4+CD25– T cells (at a ratio of one APC to
two T cells) for 5 to 7 days in complete medium and
Foxp3 expression was evaluated by FACS in CD4+ T
cells according to manufacturer’s instructions.
Assessment of circulating anti-collagen antibody titers
Concentrations of anti-bovine type II collagen antibodies
(IgG2a isotypes) were determined in plasma by enzyme-
linked immunosorbent assay (ELISA) [21]. Briefly, 96-
well plates were coated with 0.5 μg/mL of bovine type II
collagen. Nonspecific binding sites were blocked with a
2 % solution of BSA. Serial dilutions of mouse sera were
added followed by incubation with IgG2a-specific goat
anti-mouse antibody (horseradish peroxidase (HRP)-la-
beled) and 3,3'-5,5' tetramethylbenzidin (TMB) (MOSS
Inc., Pasadena, MD, USA) as substrate. Absorbance was
measured at 450 nm.
Histological analysis
Whole hind legs were harvested, cut through the sagittal
axis, fixed with 10 % neutral formalin, decalcified using
rapid decalcifier solution (Eurobio, Les Ulis, France), and
embedded in paraffin. Serial tissue sections (5 μm) were
stained with hematoxylin, eosin and saffron (Merck,
Darmstadt, Germany). Joint inflammation was evaluated
blinded by a research pathologist and determined in the
lower ankle of the two hind legs with a cumulative score
at high magnification, looking at cartilage (0 = no
change, 1 = erosion, 2 = absence) and synovial inflamma-
tion (0 = no infiltrate, 1 =middle mononuclear cell infil-
trate, 2 = dense mononuclear cell infiltrate), and a global
score for the ankle at low magnification from 0 to 5,
with a maximum score of 18 per mouse.
Statistical analysis
All data were analyzed with Prism 5 (GraphPad; La Jolla,
CA, USA) or SigmaStat 3.5 (Systat Software Inc;
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London, UK) software. Statistical significance was deter-
mined by the indicated adequate tests.
Results
Treatment of arthritic mice with intravenous apoptotic
cell infusion reduces arthritis clinical score
We have previously shown that apoptotic cell injection
allows the prevention of streptococcal cell-wall-induced
arthritis in rats [11]. This time we evaluated whether
apoptotic cell injection would allow the control of on-
going arthritis. Therefore, CIA mice with a moderate to
intense clinical score (7–8 out of 16) received an apop-
totic cell or vehicle i.v. injection. Soon after injection,
the clinical score in the apoptotic cell-treated CIA mice
was strongly reduced compared to mice receiving vehicle
(Fig. 1a). During the next week, the clinical score
remained low and did not reach the clinical score level
of control CIA mice (Fig. 1a). Indeed, when the mice
were killed we observed that the severity of histological
lesions of the joints tended to decrease, notably with
hyperplasia of the synovia and cartilage erosion (Fig. 1b,
c). In addition, we observed that the levels of anti-collagen
IgG2a antibodies were reduced in CIA mice treated by
apoptotic cells (Fig. 1d). Because apoptotic cell injection
allowed the control of the progression of arthritis, we then
evaluated whether injecting a higher number of apoptotic
cells would increase this effect. Again, CIA mice with a
score of 7–8 received 5 or 15.10e6 apoptotic cells, or ve-
hicle, and the arthritis clinical score was evaluated daily.
We did not observe any additional benefit in the reduction
of the arthritis clinical score when more apoptotic cells
were infused (Fig. 1e). Indeed, the injection of three times
more apoptotic cells did not further decrease the severity
of arthritis (Fig. 1e). This confirms our previous data
showing that apoptotic cell injection can alleviate arthritis
[11] and reinforces the fact that 5.10e6 apoptotic cell
infusion is sufficient to affect the inflammatory re-
sponse [11, 17, 20, 22].
Fig. 1 Apoptotic cell injection modulates the severity of collagen-induced arthritis (CIA). CIA mice received 5.10e6 apoptotic cells (ApoCell), or 15.10e6,
or vehicle (CIA), when they demonstrated an arthritis score of 7–8 and were monitored daily (a, e). Data are expressed as mean of group ± SEM from 5
to 10 individual animal from one to two independent experiments; *p < 0.05, **p < 0.01 and ***p < 0.001 (two-way analysis of variance with Sidak’s
multiple comparisons test). At the time the mice were killed, joint cuts were stained with HES, observed at × 25 and × 100 magnification (b), histological
lesions were scored in the rear ankles (c) (8 to 9 mice from two independent experiments; no difference, Mann-Whitney test), and anti-collagenase
IgG2a antibodies were quantified in the serum (d) (19 to 25 mice per group from four to five independent experiments; *p < 0.05, parametric
paired t test)
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Intravenous apoptotic cell injection modifies T cell
response to collagen auto-antigen
At days 8 to 10 post treatment, spleen cells were col-
lected and cultured for 4–5 days with increasing con-
centrations of collagen protein to evaluate collagen-
specific T cell proliferative response. We observed
that cell proliferation in response to collagen stimula-
tion was strongly inhibited with cells from apoptotic
cell-treated mice compared to cells from untreated
arthritic mice (Fig. 2a). This difference was not
observable using a polyclonal stimulus, CD3-specific
antibody (Fig. 2a). More importantly, we took advan-
tage of the MBT antigen, mixed with collagen in CFA
for induction of arthritis, to analyze T cell response
against another antigen, and we observed similar
cell proliferation against MTB antigen between cells
from apoptotic cell-treated and untreated CIA mice
(Fig. 2b). This strongly confirms that reduced T cell
proliferation associated with apoptotic cell injection
was related to a collagen-specific immunomodulation.
Fig. 2 Apoptotic cell injection favors the induction of collagen-specific T regulatory cells (Treg). Cells from the lymph nodes of collagen-induced arthritis
mice (CIA) receiving or not receiving apoptotic cell injection (+ApoCell) were harvested at sacrifice and cell proliferation was assessed through
5-Bromo-2’-deoxyuridine (BrDU) incorporation and counting in the presence of increasing concentrations of collagen antigen, Mycobacterium
tuberculosis (MBT), or CD3-specific antibodies, as indicated (a-c). Data are shown as mean ± SEM from one representative experiment out of
three with five mice per group; *p < 0.05, **p < 0.01, ***p < 0.001, vs. CIA group (nonparametric unpaired t test). In addition, cellularity was
assessed, and CD4+ T cell and Foxp3+ Treg percentages and absolute numbers in the spleen (d, e) and lymph nodes (LN) (f, g) were determined. Data
are shown as means from seven independent experiments; each experiment includes five mice per group; *p < 0.05, **p < 0.01 (parametric paired
Student t test). Suppressive assays were performed using Treg isolated from the spleens of the previous treated and untreated CIA mice, and added at
a different ratio into collagen-specific or MBT-specific co-cultures, or in CD3/CD28-stimulated T cell cultures, and responder T cell proliferation was
assessed by BrdU incorporation and counting (h). Data are shown as mean ± SEM from one experiment with five mice per group; **p < 0.01,
nonparametric unpaired t test
Bonnefoy et al. Arthritis Research & Therapy  (2016) 18:184 Page 5 of 13
Collagen-specific immunomodulation was also ob-
served with the cells from CIA mice receiving
15.10e6 apoptotic cells (Fig. 2c).
The collagen-specific immunomodulation that we ob-
served in association with the injection of apoptotic cells
suggests the induction of collagen-specific Treg, therefore
limiting antigen-specific T cell proliferation in response
to collagen. Although we observed similar numbers of
mononuclear cells in the spleen in CIA mice receiving or
not receiving apoptotic cells (Fig. 2d), we noted that the
absolute numbers of CD4+ T cells and Foxp3+CD25+CD4
+ Treg were increased in the spleen in CIA mice receiving
apoptotic cells (Fig. 2e). In the lymph nodes in contrast,
cellularity (Fig. 2f) and the absolute numbers of CD4+ T
cells and Treg (Fig. 2g) were decreased in CIA mice
receiving apoptotic cells. The role of Treg in collagen-
specific immunomodulation was further investigated using
sorted Treg, added into collagen-specific or MBT-specific
co-cultures or CD3/CD28-stimulated T cell culture, at a
different ratio. Our data showed that only Treg sorted
from apoptotic cell-treated CIA mice allowed the suppres-
sion of the collagen-specific T cell response, but not the
Treg sorted from untreated CIA mice (Fig. 2h, left panel).
In addition, the suppressive activity of the Treg sorted
from apoptotic-cell-treated CIA mice was restricted to
collagen antigen and not extended to MBT antigen, as
Treg from CIA or apoptotic-cell-treated CIA mice
demonstrated the same ability to limit both MBT-specific
co-culture and CD3/CD28-stimulated T cell culture
proliferation (Fig. 2h, middle and right panels). Our data
strongly demonstrate that the infusion of apoptotic cells
allows the induction of Treg in vivo with an antigenic
specificity restricted to the collagen autoantigen.
Apoptotic cell injection modulates the activation of
antigen presenting cells
The immunomodulatory properties of apoptotic cells,
and notably the induction of Treg, have been associated
with phagocyte reprogramming [7, 17, 23]. Indeed, apop-
totic cell efferocytosis generates an anti-inflammatory
microenvironment containing TGF-β [23, 24]. Plasmacy-
toïd dendritic cells have been also shown to play a major
role in apoptotic cell-induced immunomodulation [20].
We therefore analyzed pDC, cDC and macrophages
10 days after apoptotic cell injection in CIA mice and
we observed that the number of pDC was significantly
decreased in the spleen of apoptotic cell-treated CIA mice
(Fig. 3a). Although pDC from apoptotic cell-treated CIA
mice expressed more CD40 and class II IA/IE molecules
ex vivo, they responded less to CpG stimulation during a
24-h culture period (Fig. 3b). Concerning cDC, we also
observed differential expression of CD40 costimulatory
molecules ex vivo when cDC were issued from apop-
totic cell-treated mice (Fig. 3c). They were also less sensi-
tive to LPS-induced activation when from apoptotic cell-
injected CIA mice (Fig. 3c). For macrophages there was
no difference in costimulatory molecule expression and
response to LPS-induced activation (data not shown).
Fig. 3 Apoptotic cell injection favors pro-regulatory properties to antigen presenting cells (APC). Plasmacytoid dendritic cells (pDC), conventional
DC (cDC) and macrophages (macro) were isolated from the spleen of collagen-induced arthritis (CIA) mice receiving or not receiving apoptotic
cells (+ApoCell) and were quantified (a), evaluated for costimulatory and class II molecules (CD40, IAIE, respectively) expression ex vivo or after
stimulation by adequate toll-like receptor ligand (b, c), and cultured with naïve allogeneic CD4+ T cells to evaluate T regulatory cell (Treg)
induction (d). Data are shown as means from seven independent experiments; each experiment includes five mice per group; *p < 0.05, **p < 0.01
(parametric paired Student t test) (a-c). d Data from individual mouse performed in triplicate plus mean (black bar) from one of three representative
experiments; ***p < 0.001 (parametric unpaired t test). MFI mean fluorescence intensity
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Altogether, the data show that despite the ongoing arth-
ritic inflammatory response, apoptotic cell injection modi-
fies pDC and cDC functions in vivo, which then respond
less to TLR ligands ex vivo.
We further evaluated APC reprograming, i.e., whether
APC modulation by apoptotic cells in vivo was
imprinted in the APC. This was addressed by culturing
sorted APC with naïve CD4+ T cells, and then evaluating
Foxp3 acquisition in CD4+ T cells by FACS analysis. We
observed that when cultured with pDC or macrophages
isolated from CIA mice receiving apoptotic cells, naïve
CD4+ T cells demonstrated a strong commitment to the
Treg profile as attested by Foxp3 expression (Fig. 3d),
but not with cDC from apoptotic-cell-treated CIA mice
(Fig. 3d, middle panel). The data demonstrate that apop-
totic cell injection modulates in-depth APC behavior in
vivo with acquisition of pro-regulatory properties, or at
least pDC and macrophages undergo reprogramming.
Apoptotic cell injection-induced modulation of arthritis is
dependent on transforming growth factor-β
TGF-β is a master anti-inflammatory cytokine involved
in many processes to maintain immune tolerance and is
associated with the direct and indirect immunomodula-
tory properties of apoptotic cells. Thus, on the day of
apoptotic cell injection, mice also received neutralizing
anti-TGF-β antibody or control isotype antibody. Al-
though CIA mice receiving apoptotic cells plus isotype
demonstrated a reduction and stabilization of the dis-
ease, CIA mice receiving apoptotic cells plus anti-TGF-
β antibody demonstrated no reduction but an arthritic
evolution similar to control CIA mice (Fig. 4a). As a
consequence, levels of anti-collagen IgG2a antibodies
were observed similar to those observed in control
untreated CIA mice when TGF-β was neutralized in
apoptotic cell-treated CIA mice (Fig. 4b). This demon-
strates that apoptotic cell-induced immunomodulation
is associated with TGF-β.
As we observed association between alleviation of
apoptotic-cell-induced arthritis and Treg induction, we
then looked at collagen-specific cell proliferation and
observed that TGF-β neutralization restored apoptotic-
cell-induced limited proliferation to collagen (Fig. 4c).
These data suggest that TGF-β neutralization inhibits
apoptotic cell-induced collagen-specific Treg; we then
looked at Treg in the spleen and observed similar percent-
ages and absolute numbers of Treg in apoptotic cell-
treated CIA mice receiving anti-TGF-β antibody compared
to untreated CIA mice (Fig. 4d). In addition, when we
looked at the antigen specificity of Treg issued from CIA
mice treated with apoptotic cells and in the presence of
TGF-β neutralization, we did not observe any suppressive
effect of such Treg in collagen-stimulated cell co-culture
(Fig. 4e). This confirms that apoptotic cell-induced
collagen-specific Treg in vivo are dependent on TGF-β. To
further evaluate whether apoptotic cell-induced Treg in-
hibition by TGF-β neutralization was associated with
blockade of APC reprogramming by apoptotic cells, pDC
and macrophages issued from CIA mice receiving apop-
totic cells and anti-TGF-β antibody were cultured with
naïve CD4+ T cells and these were less efficient in favoring
Treg commitment (Fig. 4f). However, when we looked at
ex vivo APC response to TLR ligands, we observed that in
vivo neutralization of TGF-β did not inhibit apoptotic cell-
induced cDC or pDC resistance to TLR ligand activation
(Fig. 4g). These data demonstrate that TGF-β is im-
plicated in the generation of collagen-specific Treg
after apoptotic cell injection and in the acquisition of
pro-tolerogenic properties by pDC and macrophages.
In addition, our data highlight that apoptotic cell-
induced resistance of cDC and pDC to TLR stimula-
tion is independent of TGF-β.
Methotrexate does not interfere with intravenous
apoptotic-cell-based therapy
To propose apoptotic cell injection in humans as an ad-
vanced therapeutic medicinal product to alleviate RA,
we then evaluated apoptotic cell therapy with conven-
tional RA treatment, MTX. Arthritic mice receiving
MTX treatment alone had slight reduction in disease
(p < 0.05 vs. CIA) compared to CIA mice receiving
apoptotic cell injection, which strongly decreased the
arthritis score (p < 0.001 vs. CIA) (Fig. 5a). Co-treatment,
apoptotic cells plus MTX, demonstrated disease reduction
similar to apoptotic cell injection alone (Fig. 5a), suggest-
ing that MTX does not interfere with apoptotic cell-
induced reduction of arthritis. We also observed that
co-treatment reduced collagen-specific IgG2a antibody
levels (Fig. 5b). Looking at collagen-specific T cell prolif-
eration, co-treatment also allowed collagen-specific
immunomodulation (Fig. 5c). This demonstrates that
MTX does not inhibit apoptotic cell-induced collagen-
specific immunomodulation. Whereas spleen CD4+ T
cell and Treg numbers were not affected by MTX/apop-
totic cell co-treatment (not shown), we observed that
Treg issued from co-treated CIA mice also demon-
strated collagen-specific suppressive functions (Fig. 5d),
confirming that MTX does not inhibit apoptotic cell-in-
duced collagen-specific Treg induction. In addition,
when we assessed APC reprogramming, we observed
that MTX/apoptotic cell co-treatment did not inhibit
apoptotic cell-induced APC reprogramming in vivo, as
pDC and macrophages from co-treated CIA mice dem-
onstrated ex vivo properties to favor Treg commitment
from naïve CD4+ T cells (Fig. 5e). These data demon-
strate that apoptotic cell co-treatment with MTX fur-
ther decreases the severity of arthritis compared to
MTX alone, and that MTX does not affect apoptotic
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cell-induced collagen-specific Treg induction and APC
reprogramming mechanisms.
Apoptotic cell-based therapy synergizes with anti-TNF
antibody in collagen-induced arthritis in mice
To further address the feasibility of apoptotic cell injec-
tion in RA, we evaluated apoptotic cell injection and
anti-TNF antibody effect. Apoptotic cell injection or
anti-TNF blockade demonstrated a similar reduction in
arthritis (Fig. 6a), but, when co-administered, apoptotic
cells and anti-TNF antibody demonstrated a stronger re-
duction in the severity of arthritis (Fig. 6a). Looking at
the mechanisms, whereas anti-TNF antibody treatment
alone did not favor collagen-specific immunomodulation
compared to apoptotic cell injection, apoptotic cell/anti-
TNF antibody co-injection induced collagen-specific
immunomodulation, but to a lower extent to that ob-
served with apoptotic cell injection alone (Fig. 6b). Also,
anti-TNF antibody treatment favored a higher number
of spleen Treg, that were maintained in the presence of
apoptotic cells (Fig. 6c). So far, our data demonstrate
that apoptotic cell injection with TNF neutralization
strongly reduces arthritis severity and allows an in-
creased number of spleen Treg.
Fig. 4 Apoptotic cell-induced immunomodulation in mice with collagen-induced arthritis (CIA) is dependent on transforming growth factor
(TGF)-β. CIA mice that received or did not receive apoptotic cells, with or without anti-TGF-β blocking antibody were scored daily (a). Data are
shown as mean ± SEM of five mice per group from one of two representative experiments; *p < 0.05, **p < 0.01 (Friedman test analysis of
variance (ANOVA) with Dunn's multiple comparisons test). Anti-collagen IgG2a antibodies (Ab) were quantified in plasma (b). Data from 5 to 16
mice from two to three independent experiments (no difference, Kruskal-Wallis test ANOVA with Dunn’s multiple comparisons test). Lymph node
cells were collected, cultured, and T cell proliferation in response to collagen protein or CD3-specific Ab stimulations was evaluated (c). Data are
shown as mean ± SEM from one of two representative experiments; *p < 0.05, **p < 0.01 (nonparametric unpaired t test). Percent and absolute
number of Foxp3+ T regulatory cells (Treg) were evaluated in the spleen (d) and suppressive assays were performed by isolating and adding Treg
at a different ratio into collagen-specific cultures and responder T cell proliferation was assessed (e). Data are shown as mean ± SEM from one
experiment (d Kruskal-Wallis test ANOVA with Dunn’s multiple comparisons test; e Friedman test ANOVA with Dunn’s multiple comparisons test).
Plasmacytoid dendritic cells (pDC), conventional dendritic cells (cDC) and macrophages (macro) were isolated and cultured with naïve allogenic T
cells to determine Treg polarization (f), and their response to TLR ligand was assessed through evaluation of CD40 costimulatory molecule expression (g).
Data from individual mouse plus mean (black bar) from one experiment representative of four are shown; *p< 0.05, ***p< 0.001 (f ordinary one-way
ANOVA with Tukey’s multiple comparisons test; g Kruskal-Wallis test ANOVA with Dunn’s multiple comparisons test). BrDU 5-Bromo-2’-deoxyuridine
Bonnefoy et al. Arthritis Research & Therapy  (2016) 18:184 Page 8 of 13
When APC reprogramming was evaluated, pDC and
cDC demonstrated less response to TLR ligand-induced
activation when issued from CIA mice receiving anti-
TNF antibody, with or without apoptotic cell injection
(Fig. 6d). Macrophage response to TLR was again not af-
fected by either treatment (not shown). When issued
from anti-TNF/apoptotic cell-treated CIA mice, pDC
and macrophages then allowed Treg commitment from
naïve CD4+ T cells (Fig. 6e). This was not so with anti-
TNF antibody injection alone (Fig. 6e). Our data demon-
strate that anti-TNF antibody treatment alone modulates
arthritis severity by favoring increase in Treg but not
collagen-specific Treg or APC reprogramming with pro-
regulatory properties. When administered with apoptotic
cells, a stronger modulation of arthritis severity was ob-
served associated with a strong reduction of collagen-
Fig. 5 Methotrexate (MTX) does not inhibit apoptotic cell-induced reduction of arthritis severity. Collagen-induced arthritis (CIA) mice received or
did not receive apoptotic cells, with or without MTX, or MTX alone and were scored daily (a). Data are shown as mean ± SEM of five mice per
group from one of two representative experiments; *p < 0.05 vs. CIA, ***p < 0.001 (two-way analysis of variance (ANOVA) with Sidak's multiple
comparisons test). Anti-collagen IgG2a antibodies (Ab) were quantified in plasma (b). Data from 5 to 16 mice from two independent experiments
plus mean (bar graph); *p < 0.05 (Kruskal-Wallis test ANOVA with Dunn's multiple comparisons test). Lymph node cells were collected, cultured
and T cell proliferation was evaluated in response to collagen antigen or CD3-specific Ab stimulations (c). Data are shown as mean ± SEM from
one of two representative experiments; *p < 0.05, **p < 0.01 (nonparametric unpaired t test). T regulatory cells (Treg) were isolated and added at
different ratio into co-cultures specific for collagen and responder T cell proliferation was assessed (d). Data are shown as mean ± SEM from one
experiment; **p < 0.05, ***p < 0.001 (nonparametric unpaired t test). Plasmacytoid DC, cDC and macrophages were isolated and cultured with
naïve allogeneic T cells to determine Treg polarization (e). Data from individual mouse plus mean (black bar) from one experiment representative
of two are shown; **p < 0.01, ***p < 0.001, ****p < 0.0001 (ordinary one-way ANOVA with Tukey’s multiple comparisons test).
BrDU 5-Bromo-2’-deoxyuridine
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specific T cell response and the gain of pro-regulatory
properties by APC.
Discussion
Despite significant improvement in the management
of patients with RA through the development of innova-
tive drugs (e.g., biologic agents) [25, 26], new therapeutic
strategies are constantly needed. Indeed, some patients
are still non-responsive to the current drugs and toxic-
ities, or contraindications have been reported [4, 26].
Most of the biologic agents target inflammatory cytokines
or B cells, while limited biologic agents (i.e., abatacept)
neutralize T cell activation [25, 26]. There is no approved
drug that targets APC, such as dendritic cells, while APC
orchestrate the immuno-pathogenic response.
Apoptotic cell-based therapy can be an interesting ap-
proach as apoptotic cell infusion has been shown to
prevent experimental RA [9–12] and to target T-cell-
mediated diseases associated with dysregulated inflam-
matory cytokine secretion and APC dysfunction [6]. A
dysregulated intricate interplay between T cells, macro-
phages and inflammatory cytokines is implicated in RA
pathophysiology. Here, we used a mouse model of arth-
ritis that recapitulates RA [27]. We report in this model
that i.v. administration of apoptotic cells is able to treat
ongoing arthritis and is associated with the reprogramming
Fig. 6 Apoptotic cell injection and anti-TNF therapy synergize to control ongoing arthritis. Collagen-induced arthritis (CIA) mice received or did
not receive apoptotic cells, with or without anti-TNF blocking antibody and were scored daily (a). Data are shown as mean ± SEM of five mice
per group from one experiment; *p < 0.05 (two-way analysis of variance (ANOVA) with Sidak's multiple comparisons test). Lymph node cells
were collected, cultured, and T cell proliferation was evaluated in response to collagen protein or CD3-specific antibody (Ab) stimulations (b). Data are
shown as mean ± SEM from one experiment; *p < 0.05, **p < 0.01 vs. CIA (nonparametric unpaired t test). Percentages and absolute numbers of Foxp3 T
regulatory cells (Treg) were evaluated in the spleen (c). Data are shown as individual mouse plus mean (black bar) from one experiment; *p < 0.05, **p <
0.01 (Kruskal-Wallis ANOVA test with Dunn’s multiple comparisons test). Plasmacytoid dendritic cells (pDC), conventional dendritic cells (cDC) and
macrophages (Macro) were isolated to evaluate their response to toll-like receptor (TLR) ligand stimulation through evaluation of CD40 costimulatory
molecule expression (d) and cultured with naïve allogeneic CD4+ T cells to determine Treg polarization (e). Data from individual mouse plus mean
(black bar) from one experiment; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001(d Kruskal-Wallis ANOVA test with Dunn’s multiple comparisons test,
e ordinary one-way ANOVA test with Tukey’s multiple comparisons test) BrDU 5-Bromo-2’-deoxyuridine, MFI mean fluorescence intensity
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of APC, in particular pDC and macrophages, and induc-
tion of auto-antigen-specific Treg. Moreover, this new
therapeutic approach can be used alongside either MTX
or anti-TNF therapy (i.e., two standard treatments of RA)
with similar efficacy. This allows us to propose this ap-
proach in clinical settings, as already performed for
the prevention of GvHD after allogeneic hematopoietic
cell transplantation [16]. As observed in mice, patients
would have to receive such a treatment when presenting
with a moderate 20 % improvement in the American
College of Rheumatology (ACR20) clinical score for
a higher therapeutic effect.
The novelty of this study resides in the use of apop-
totic cell infusion to treat ongoing arthritis, and not, as
previously reported by us [11] and others [9, 10, 12], to
prevent the induction of arthritic disease. The analysis of
the mechanisms involved in this therapeutic effect of i.v.
apoptotic cell infusion identifies the modulation of APC
functions and reprogramming, induction of auto-
antigen-specific Treg, and reduction of circulating auto-
antibody levels. Adoptive transfer of polyclonal Treg has
been already shown to inhibit ongoing arthritis in the
CIA model, but this approach only ameliorated the se-
verity of CIA without affecting collagen-specific T and B
cell responses [28]. This is in contrast with our present
data showing that apoptotic cell infusion through the
direct targeting of APC function affects collagen-specific
immune response. The CIA model, and more precisely
the immunization of mice with bovine type II collagen
in CFA containing MBT, allowed us to appreciate the
antigenic specificity of apoptotic cell-induced Treg with
a selective induction of collagen-specific Treg, but not
MBT-specific Treg. The precise mechanisms allowing
this specific increase in auto-antigen Treg (here collagen
as the model antigen), but not infectious antigen (MBT),
remains to be determined. One may believe that distinct
APC subsets or the antigen-presenting pathways are in
charge of auto-antigen or infectious antigen and that this
subset or pathway is differentially targeted by apoptotic
cell infusion. This remains to be determined.
We previously observed that pDC were sensitive to
factors issued from macrophages eliminating apoptotic
cells but not to apoptotic cells directly [20], in contrast
to DC or macrophages [23]. Here, macrophages will be
the first ones to interact and eliminate apoptotic cells
injected i.v., in contrast to cDC. Then, as previously re-
ported [20], this microenvironment provided by macro-
phages eliminating apoptotic cells will directly favor
pDC to acquire a tolerogenic profile, notably with the de
novo production of TGF-β, favoring pDC to allow gener-
ation of antigen-specific Treg [19]. However, this micro-
environment only allowed cDC to favor less Th1
polarization ex vivo (not shown). It seems that apoptotic
cells differentially affect cDC, as when engulfed by cDC
they favored cDC pro-tolerogenic reprogramming, but
when engulfed by macrophages, the issued factors only
limited their pro-inflammatory properties.
Similar observations have been performed in another
apoptotic cell-based therapy implicating in vivo induc-
tion of apoptosis and phagocyte administration together
with auto-antigen-derived peptides [29]. Despite differ-
ences in the process and the targeted diseases (EAE and
type 1 diabetes), this latter approach described similar
mechanisms to our therapy, including: apoptotic cell
phagocytosis, TGF-β-dependent Treg generation [29].
Induction of collagen-specific Treg by apoptotic cell
injection is inhibited by TGF-β neutralization, as previ-
ously reported in other apoptotic cell-based therapies
[17, 29]. Most of the studied effects observed here after
apoptotic cell treatment are dependent on TGF-β and
neutralization of this cytokine prevents improvement in
arthritis. Anti-collagen IgG2a antibody levels reached
the levels found in untreated arthritic mice when neu-
tralizing anti-TGF-β antibody is infused together with
apoptotic cells. This confirms our previous data with
anti-donor allo-antibodies in the settings of bone mar-
row graft rejection [30]. In fact, only APC reprogram-
ming persisted after neutralization of TGF-β in the
setting of apoptotic cell infusion in arthritic mice. This
appears logical as TGF-β is secreted by APC after apop-
totic cell removal [23, 31] but elimination of apoptotic
cells (called efferocytosis) per se is sufficient to modify
several APC functions, including the refractory response
to TLR ligands [32]. The effects on APC functions in-
duced after apoptotic cell treatment are conserved when
apoptotic cells are infused together with anti-TNF ther-
apy. This can be an encouraging argument to combine
both treatments.
Association of new therapeutic approaches with drugs
used routinely is infrequently assessed in experimental
models. To the best of our knowledge, this has only
been tested in the context of apoptotic cell infusion in
one study by our group in the settings of allogeneic
hematopoietic cell transplantation [18]. Here, we re-
ported that the therapeutic effects of apoptotic cell infu-
sion are conserved in the presence of MTX or anti-TNF
therapy. However, there are differences in apoptotic cell-
induced mechanisms. For instance, MTX abolishes the
diminution of anti-collagen auto-antibodies induced by
apoptotic cell injection. MTX, a traditional DMARD
with folate antagonist and anti-inflammatory activity,
remains the gold standard treatment for RA. Several po-
tential mechanisms of MTX activity have been proposed,
but the precise mechanism(s) of action in RA are still
not well-understood [33]. In animal models, the effects
of MTX have been attributed to MTX-induced anti-
inflammatory adenosine production [33]. This produc-
tion is mediated by CD39 and CD73 ectoenzymes [33].
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Both ecto-enzymes are known to be expressed by Treg
and represent one of the suppressive mechanisms of
Treg [34].
MTX treatment demonstrated a limited effect on arth-
ritis severity when started in mice presenting with an ad-
vanced arthritic clinical score of 8. In this context, after
the injection of apoptotic cells, collagen-specific Treg
are still generated. We can propose that apoptotic cell
therapy in CIA favors the generation of Treg from exist-
ing antigen-specific T cells, as no cell proliferation is
needed and MTX can exert an anti-proliferative effect
even if the cytostatic effect of MTX is still a matter of
debate in RA [33]. However, the origin of antigen-
specific Treg in our settings needs to be further investi-
gated. Thus, through the induction of an anti-
inflammatory microenvironment, apoptotic cells can
favor the establishment of collagen-specific Treg-
associated long-term tolerance. Anti-TNF therapy is syn-
ergic with apoptotic cell infusion on clinical outcomes,
but we did not identify any supplementary effects on the
immune parameters studied when anti-TNF antibody is
combined with apoptotic cells compared with apoptotic
cells alone. This suggests that additional mechanism(s)
such as the complete neutralization of circulating TNF,
may participate in the synergic clinical outcomes. The
relationship between TNF, anti-TNF therapy and Treg
plasticity and suppressive functions is complex and re-
mains a matter of debate [35], notably in humans [36,
37]. Here, anti-TNF therapy does not affect the number
of splenic Treg or the collagen-specific Treg suppressive
function.
Conclusions
We provide here a novel medicinal product for advanced
therapy for RA, which is compatible with first-line MTX
treatment and synergistic with anti-TNF biological second-
line treatment. Through the generation of antigen-specific
Treg by APC reprogramming by apoptotic cell efferocyto-
sis, this approach offers an innovative therapeutic solution
to patients with RA that is refractory and non-responsive
to current treatments.
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